FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2005
AVI BioPharma, Inc.
(Exact name of registrant as specified in its charter)
|
Oregon |
|
0-22613 |
|
93-0797222 |
|
(State or other jurisdiction of |
|
(Commission |
|
(IRS Employer |
|
incorporation or organization) |
|
File Number) |
|
Identification Number) |
One S.W. Columbia, Suite 1105
Portland, OR 97258
(Address of principal executive offices)
(503) 227-0554
Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On November 4, 2005, AVI BioPharma, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2005. The press release is attached to this Form 8-K as Exhibit 99.1.
Item 7.01 Regulation FD Disclosure
Information furnished under Item 2.02.
Item 9.01 Financial Statements, Pro Forma Financial Information and Exhibits.
Exhibits
99.1. Press release dated November 4, 2005, announcing financial results for the three and nine months ended September 30, 2005.
***
Note: The information contained in this report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.
2
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on November 4, 2005.
|
|
AVI BioPharma, Inc. |
||
|
|
|
||
|
|
By: |
/s/ ALAN P. TIMMINS |
|
|
|
|
|
|
|
|
|
Alan P. Timmins |
|
|
|
|
President and Chief Operating Officer |
|
3
EXHIBIT INDEX
99.1. Press release dated November 4, 2005, announcing financial results for the three and nine months ended September 30, 2005.
4